29 completed, 5 not yet recruiting, 4 unknown, 2 active not recruiting. 17 Phase 4, 12 Phase 3, 9 Phase 2, 4 Not applicable, 2 Phase 1.
Follow silodosin: new trials by email Literature Review of silodosin trials Research Report on silodosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction Silodosin 8 mg, Placebo - Voiding Dysfunction, Female LUTS | Phase 2 | Not yet recruiting | Jaber Al Ahmad Al Sabah Hospital | 150 | 2026-10-01 | 2026-09-16 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis Silodosin 8 mg, Placebo - Multiple Sclerosis, Lower Urinary Track Symptoms | Phase 4 | Recruiting | Atlantic Health System | 60 | 2026-04-01 | 2026-05-29 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction alpha blocker monotherapy Tamsulosin, alpha blockers Tamsulosin and Silodosin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Active not recruiting | Mansoura University | 140 | 2025-10-12 | 2026-09-11 |
| A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia H077 sustained-release tablet, Silodosin capsules Control Group - Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Phase 3 | Not yet recruiting | Shanghai Huilun Pharmaceutical Co., Ltd. | 728 | 2025-08-01 | 2025-08-28 |
| Silodosin in Facilitating Flexible Uretroscopy Preoperative sioldosin to facilitate ureteric access sheath insertion in RIRS, ureteric access sheath insertion in RIRS without silodosin (Placebo) - Stone Ureter, Stone, Kidney | Not applicable | Active not recruiting | Ain Shams University | 42 | 2025-02-01 | 2025-07-16 |
| Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi Tamsulosin Oral Capsule - Ureteric Stone of Lower Third of Ureter | Phase 4 | Completed | Getz Pharma | 240 | 2024-09-01 | 2025-08-20 |
| Silodosin vs Placebo in the Treatment of Female LUTS Silodosin, Placebo - Lower Urinary Tract Symptoms | Phase 3 | Unknown | Mansoura University | 278 | 2023-11-01 | 2023-11-02 |
| Comparative Study for Medical Therapy for Lower Ureteral Stones • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf - Lower Ureteral Stones | Phase 3 | Completed | Beni-Suef University | 180 | 2023-11-01 | 2024-11-27 |
| Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones Silodosin - Tamsulosin, Silodosin | Not applicable | Completed | Fatima Jinnah Medical University | 200 | 2023-10-01 | 2025-05-31 |
| Silodosin in Retrograde Intrarenal Surgery Silodosin 8 mg, Placebo - Urolithiasis | Phase 3 | Completed | Ain Shams University | 60 | 2023-04-04 | 2024-07-16 |
| The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule - Prostatic Hyperplasia | Phase 2 | Completed | Beni-Suef University | 140 | 2023-02-01 | 2024-03-20 |
| Silodosin in Management of Lower Ureteral Stones Silodosin - Stone, Kidney | Phase 1 / Phase 2 | Completed | Syrian Private University | 100 | 2022-10-20 | 2024-04-24 |
| The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Silodosin Capsules, Tamsulosin - Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Phase 4 | Completed | Xintian Pharmaceutical | 110 | 2022-09-21 | 2026-09-09 |
| COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI Silodosin, Tamsulosin - Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi | Phase 1 | Completed | Armed Forces Institute of Urology, Rawalpindi | 142 | 2022-09-01 | 2023-03-30 |
| The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH Silodosin, Tamsolusin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Completed | Shanghai Huilun Pharmaceutical Co., Ltd. | 110 | 2022-07-18 | 2025-08-21 |
| Silodosin vs Tamsulosin as MET Silodosin, Tamsulosin - Stone, Urinary | Phase 3 | Unknown | Princess Margaret Hospital, Hong Kong | 80 | 2022-05-31 | 2022-10-06 |
Showing 20 of 45. Sign in to see all of them.
Prostatic Hyperplasia (20) · Kidney Calculi (6) · Lower Urinary Tract Symptoms (5) · Ureterolithiasis (3) · Iris Diseases (2) · Nocturia (2) · Ureteral Calculi (2) · Urinary Calculi (2) · Urolithiasis (2) · Multiple Sclerosis (1) · Premature Ejaculation (1) · Prostatic Neoplasms (1) · Prostatitis (1) · Renal Colic (1) · Trichinellosis (1)
Watson Pharmaceuticals (6) · JW Pharmaceutical (5) · Ain Shams University (3) · Beni-Suef University (3) · Albert Einstein Healthcare Network (2) · Benha University (2) · Kissei Pharmaceutical Co., Ltd. (2) · Mansoura University (2) · Mohsen Pourazizi (2) · RECORDATI GROUP (2) · Shanghai Huilun Pharmaceutical Co., Ltd. (2) · Armed Forces Institute of Urology, Rawalpindi (1) · Atlantic Health System (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Centre Hospitalier Departemental Vendee (1)
Egypt (9) · United States (9) · South Korea (5) · China (3) · Pakistan (3) · Taiwan (3) · Japan (2) · Bangladesh (1) · Canada (1) · France (1) · Hong Kong (1) · Italy (1) · Kuwait (1) · Syria (1) · United Kingdom (1)
Kim Caramelli, MS (2) · Lawrence Hill, PharmD, RPh (2) · Cheng Cheng Wang, M.D Ph.D (1) · Cheng-Hsing Hsieh, MD (1) · Christopher R Chapple, MD (1) · Christopher Re Chapple, BSc MD (1) · Chul-Hee Park (1) · D.G. Moon, Prof (1) · D.Y. Yang, Prof (1) · Duk-Yoon Kim (1) · G.S. Park, Prof (1) · Gwan-Joong Joo, Ph.D (1) · Hee-Chang Jung (1)
PMID 21135869, PMID 23234617, PMID 19371887, PMID 19815265, PMID 21109344, PMID 21571345, PMID 21664068, PMID 25712312, PMID 33524970, PMID 3795356, PMID 8621278